Neuroendocrine Carcinoma of Unknown Primary Origin
📧 Sign up to get email alerts when something new happens for Neuroendocrine Carcinoma of Unknown Primary Origin.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-02-04Clinical Trial Update: Refractory Advanced diGestive Neuroendocrine Carcinomas Treated With tARlatamab [Phase 2]
This is a Phase 2 clinical trial update evaluating tARlatamab for refractory advanced digestive neuroendocrine carcinomas. The study is curr…
-
CLINICAL_TRIALS research · 2026-01-13Clinical Trial Update: Trial of FOLFIRI + Zimberelimab + Domvanalimab vs FOLFIRI With a Hybrid Synthetic Control Arm in Second Line Treatment of Neuroendocrine Carcinoma of Gastro-enteropancreatic or Unknown Origin (REWENEC 01) [Phase 2]
Phase 2 clinical trial assessing FOLFIRI plus zimberelimab and domvanalimab versus FOLFIRI with a synthetic control arm in second-line neuro…